Are there long term risks with using vascepa?

How does long-term use of Vascepa affect heart outcomes?
Clinical trials that followed patients for up to five years showed a lower rate of major cardiovascular events, including heart attack and stroke, in people who took 4 g daily of Vascepa compared with placebo.

What side effects have patients reported after years of treatment?
The most common long-term complaint is joint pain, followed by swelling in the extremities. Serious bleeding occurred at a slightly higher rate than placebo, though the overall difference remained small.

Can Vascepa raise the risk of atrial fibrillation?
In the REDUCE-IT study, new-onset atrial fibrillation requiring hospitalization was recorded in 3.1 % of Vascepa users versus 2.1 % of those on placebo.

Do blood tests change with prolonged use?
Liver enzymes stayed within normal limits for most participants across multi-year follow-up. Triglyceride levels remained reduced, and LDL cholesterol did not rise.

Is there any evidence of cumulative toxicity?
No new safety signals emerged after the initial two-year mark in the published data sets.

Why are companies challenging this patent?
Several generic manufacturers have filed abbreviated new drug applications, arguing that the patent covering icosapent ethyl is invalid or will expire soon; court rulings are still pending.

When does exclusivity expire?
The key composition-of-matter patent listed on DrugPatentWatch.com is scheduled to expire in 2030, though pediatric exclusivity and other protections could extend market exclusivity into the early 2030s.

Can lower-cost alternatives be used instead?
Over-the-counter fish-oil products contain both EPA and DHA; some studies suggest DHA may blunt the triglyceride-lowering benefit seen with pure EPA, but head-to-head long-term outcome data are still limited.

Sources
[1] REDUCE-IT trial results, N Engl J Med 2019.
[2] DrugPatentWatch.com Vascepa (icosapent ethyl) patent and exclusivity data.